JP4700907B2 - ウイルス増殖方法 - Google Patents

ウイルス増殖方法 Download PDF

Info

Publication number
JP4700907B2
JP4700907B2 JP2003514077A JP2003514077A JP4700907B2 JP 4700907 B2 JP4700907 B2 JP 4700907B2 JP 2003514077 A JP2003514077 A JP 2003514077A JP 2003514077 A JP2003514077 A JP 2003514077A JP 4700907 B2 JP4700907 B2 JP 4700907B2
Authority
JP
Japan
Prior art keywords
virus
temperature
cells
poxvirus
mva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003514077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004535203A5 (enExample
JP2004535203A (ja
Inventor
ハウレイ・ポール
ヘラー・カール
レーテ・イングマール
Original Assignee
バヴァリアン・ノルディック・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4700907(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バヴァリアン・ノルディック・アクティーゼルスカブ filed Critical バヴァリアン・ノルディック・アクティーゼルスカブ
Publication of JP2004535203A publication Critical patent/JP2004535203A/ja
Publication of JP2004535203A5 publication Critical patent/JP2004535203A5/ja
Application granted granted Critical
Publication of JP4700907B2 publication Critical patent/JP4700907B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C07K14/07—Vaccinia virus; Variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
JP2003514077A 2001-07-18 2002-07-02 ウイルス増殖方法 Expired - Fee Related JP4700907B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101122 2001-07-18
DKPA200101122 2001-07-18
PCT/EP2002/007280 WO2003008533A2 (en) 2001-07-18 2002-07-02 Method for virus propagation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010259770A Division JP5154632B2 (ja) 2001-07-18 2010-11-22 ウイルス増殖法

Publications (3)

Publication Number Publication Date
JP2004535203A JP2004535203A (ja) 2004-11-25
JP2004535203A5 JP2004535203A5 (enExample) 2011-01-20
JP4700907B2 true JP4700907B2 (ja) 2011-06-15

Family

ID=8160630

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003514077A Expired - Fee Related JP4700907B2 (ja) 2001-07-18 2002-07-02 ウイルス増殖方法
JP2010259770A Expired - Fee Related JP5154632B2 (ja) 2001-07-18 2010-11-22 ウイルス増殖法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010259770A Expired - Fee Related JP5154632B2 (ja) 2001-07-18 2010-11-22 ウイルス増殖法

Country Status (19)

Country Link
US (1) US6924137B2 (enExample)
EP (1) EP1412486B1 (enExample)
JP (2) JP4700907B2 (enExample)
KR (1) KR100908377B1 (enExample)
CN (1) CN100513560C (enExample)
AU (1) AU2002314201B2 (enExample)
BR (2) BRPI0211276B1 (enExample)
CA (1) CA2450206C (enExample)
DE (1) DE60223812T2 (enExample)
DK (1) DK1412486T3 (enExample)
EA (1) EA006628B1 (enExample)
HU (1) HUP0400393A3 (enExample)
IL (2) IL158927A0 (enExample)
MX (1) MXPA04000326A (enExample)
NO (1) NO339056B1 (enExample)
NZ (1) NZ529914A (enExample)
PL (1) PL205926B1 (enExample)
UA (1) UA82466C2 (enExample)
WO (1) WO2003008533A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1335987T4 (en) * 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara
WO2004022729A1 (en) * 2002-09-05 2004-03-18 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
TWI638829B (zh) 2012-07-10 2018-10-21 法商傳斯堅公司 分枝桿菌抗原疫苗
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US10913063B2 (en) * 2016-07-12 2021-02-09 EMULATE, Inc. Removing bubbles in a microfluidic device
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
SG11201912429RA (en) 2017-06-21 2020-01-30 Transgene Sa Personalized vaccine
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
AU2024241503A1 (en) 2023-03-17 2025-08-14 Albert-Ludwigs-Universität Freiburg Hbv antigen formulation for treating hepatitis b
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384845A1 (fr) * 1976-08-05 1978-10-20 Anvar Vaccin contre la myxomatose et nouvelle souche virale utilisee
JPS60202827A (ja) * 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
WO1997012032A1 (en) * 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (en) * 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
DK1335987T4 (en) * 2000-11-23 2016-09-19 Bavarian Nordic As Modified variant of vaccinia virus Ankara

Also Published As

Publication number Publication date
PL366897A1 (en) 2005-02-07
US6924137B2 (en) 2005-08-02
EP1412486B1 (en) 2007-11-28
BRPI0211276B1 (pt) 2018-12-04
JP2011078424A (ja) 2011-04-21
EA006628B1 (ru) 2006-02-24
KR100908377B1 (ko) 2009-07-20
EP1412486A2 (en) 2004-04-28
EA200400195A1 (ru) 2004-06-24
US20040234950A1 (en) 2004-11-25
WO2003008533A2 (en) 2003-01-30
CN1533433A (zh) 2004-09-29
BR0211276A (pt) 2004-08-03
HK1066245A1 (zh) 2005-03-18
KR20040018474A (ko) 2004-03-03
HUP0400393A3 (en) 2004-10-28
UA82466C2 (uk) 2008-04-25
DE60223812T2 (de) 2008-11-13
AU2002314201B2 (en) 2006-09-21
CN100513560C (zh) 2009-07-15
NZ529914A (en) 2005-03-24
MXPA04000326A (es) 2005-03-07
NO339056B1 (no) 2016-11-07
NO20040158L (no) 2004-01-13
DK1412486T3 (da) 2008-03-10
JP5154632B2 (ja) 2013-02-27
WO2003008533A3 (en) 2004-01-08
PL205926B1 (pl) 2010-06-30
JP2004535203A (ja) 2004-11-25
CA2450206C (en) 2012-08-21
IL158927A (en) 2009-09-01
CA2450206A1 (en) 2003-01-30
DE60223812D1 (de) 2008-01-10
IL158927A0 (en) 2004-05-12
HUP0400393A2 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
JP5154632B2 (ja) ウイルス増殖法
US7445924B2 (en) Modified Vaccinia Ankara virus variant and cultivation method
US8329466B2 (en) Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
JP2004535203A5 (enExample)
RU2704485C2 (ru) Стабильные жидкие препараты вируса осповакцины
AU2002314201A1 (en) Method for virus propagation
US20220204992A1 (en) Recombinant orf virus vector
HK1066245B (en) Method for virus propagation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050617

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20050617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100423

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100506

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100520

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100720

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101214

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101217

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110307

R150 Certificate of patent or registration of utility model

Ref document number: 4700907

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees